Business Context and Reporting Period
This Form 8-K Current Report was filed by Septerna, Inc. (SEPN) on September 25, 2025, with the earliest event reported on that same date. The filing primarily addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on personnel appointments rather than financial performance data.
Material Changes
- Board Expansion: The Board of Directors expanded from seven to eight members.
- New Appointment: Keith Gottesdiener, M.D., was appointed as a Class I director effective September 25, 2025, for a three-year term expiring in 2028.
- Committee Roles: Effective September 26, 2025, Dr. Gottesdiener was appointed to the Compensation Committee and named Chair of the Research and Development (R&D) Committee.
- Independence: The Board determined Dr. Gottesdiener is independent under Nasdaq listing standards and SEC regulations.
Compensation and Governance Details
Dr. Gottesdiener will receive compensation in accordance with the Company's Non-Employee Director Compensation Policy. Additionally, he will receive an annual cash retainer of $12,000 for his service as Chair of the R&D Committee, paid quarterly in arrears and pro-rated based on days served. No material transactions or family relationships requiring disclosure under Item 404(a) of Regulation S-K were identified.
Investor Verification Checklist
- Verify the full text of the Non-Employee Director Compensation Policy referenced in the Definitive Proxy Statement filed on April 29, 2025.
- Review the press release dated September 29, 2025 (Exhibit 99.1) for additional context on Dr. Gottesdiener's background.
- Confirm the updated composition of the Board and its committees in subsequent filings.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.